Currently, there are 108.11M common shares owned by the public and among those 58.92M shares have been available to trade.
The company’s stock has a 5-day price change of 74.81% and -5.76% over the past three months. TNGX shares are trading -25.89% year to date (YTD), with the 12-month market performance down to -70.64% lower. It has a 12-month low price of $1.03 and touched a high of $12.02 over the same period. TNGX has an average intraday trading volume of 741.36K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 61.07%, 53.22%, and -48.75% respectively.
Institutional ownership of Tango Therapeutics Inc (NASDAQ: TNGX) shares accounts for 55.90% of the company’s 108.11M shares outstanding.
It has a market capitalization of $248.22M and a beta (3y monthly) value of 1.03. The earnings-per-share (ttm) stands at -$1.21. Price movements for the stock have been influenced by the stock’s volatility, which stands at 28.36% over the week and 16.42% over the month.
Earnings per share for the fiscal year are expected to decrease by -14.29%, and 2.84% over the next financial year. EPS should shrink at an annualized rate of -5.61% over the next five years, compared to 7.47% over the past 5-year period.
Looking at the support for the TNGX, a number of firms have released research notes about the stock. Jefferies stated their Buy rating for the stock in a research note on July 17, 2024, with the firm’s price target at $19. Piper Sandler was of a view on February 12, 2024 that the stock is Overweight, while B. Riley Securities gave the stock Buy rating on December 08, 2023, issuing a price target of $16. H.C. Wainwright on their part issued Buy rating on October 20, 2022.
